travel tech

B2B travel company grows its Houston presence

Real-time inventory software enables travelers to book a last minute flight and have their boarding passes in hand at security a few minutes later. But that technology isn't utilized in other aspects of a vacation — tour companies, for example. That's where San Francisco-based Xola comes in.

Scott Zimmerman and his co-founder Anush Ramani realized real-time technology was a glaring hole in a multi-billion-dollar business. It's why they founded Xola, a booking and marketing software system designed for tour and activity companies.

"So many smaller tour companies operate with pen and paper," Zimmerman explained. "And for many cities and countries, tourism is the number-two or number-three industry — it's a huge driver of economic growth. It's a $120 billion global market."

They created Xola as a B2B solution that created a platform for operators to promote their offerings, and allow customers to purchase tours and activities. Meanwhile, Xola's custom-design software platform managed the tour inventory and payments, providing real-time inventory management.

Since its inception in 2011, Xola has emerged as a leading B2B solution for travel industry operators. The company started in San Francisco, but opened an office in Houston in 2016 in the Heights Clock Tower. Xola's Houston operation began with six people; today, it employs 17. Zimmerman says he sees potential to grow the team with additional marketing, sales, and support staff.

"We serve customers around the world, and Houston has everything we need to continue our growth."

Zimmerman acknowledged the cost of doing business in the Bay Area is expensive, but when he went looking for cities in which to expand, price wasn't his only concern.

"We wanted a large metropolitan area, with a diverse ecosystem, good universities, a great talent pool, a high quality of life and an affordable cost of living. Houston has all these things. And the more I get to know the city, I realize just how much it has going on."

Zimmerman said that the city has "totally exceeded" his expectations in terms of Xola's growth. He said every one of the Houston employees is wonderful to work with, and loves that they come from diverse cultural and educational backgrounds.

"I can't quite describe what the office is like, but there's a great energy and enthusiasm. [The team] easy to work with. It's been fun in that regard."

Zimmerman said that Houston's talent pool is so extensive, he can't imagine "ever exhausting" the city's resources. He also sees Houston as an asset for Xola's continued growth. The company currently has offices in San Francisco, Houston, Bangalore, and Belgrade and anticipates more expansion in the coming years. Xola's ticketing and software system has received multiple five-star reviews from its customers, who praise not only its ease of operation, but also the company's stellar customer service. In fact, Xola just won a 2018 Ease of Use Award from Capterra.

"In addition to Xola's core booking system, we're building next-generation automated marketing features that help our customers maintain a competitive edge. And our Houston team will continue to grow as we do, so we can continue to serve markets around the world."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted